Viking Therapeutics (VKTX) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free VKTX Stock Alerts $67.00 -2.06 (-2.98%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 6:47 AM | fool.com3 Monster Stocks in the Making You Can Buy Right NowMay 18 at 5:12 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by Raymond JamesMay 18 at 5:12 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Stock Rating Reaffirmed by Truist FinancialMay 18 at 1:01 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by StockNews.comMay 17 at 3:02 PM | investorplace.comPharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?May 17 at 2:16 PM | msn.comRaymond James Upgrades Viking Therapeutics (VKTX)May 17 at 9:16 AM | baystreet.caStock Sell Alerts: Cisco Systems, Viking Therapeutics, B. RileyMay 17 at 9:00 AM | fool.comIs Viking Therapeutics Stock a Buy?May 16 at 3:59 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Down to $78.01Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down to $78.01May 16 at 3:28 PM | msn.comViking falls after Roche’s obesity drug data; RayJay upgrades (update)May 16 at 3:16 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Raised to "Strong-Buy" at Raymond JamesRaymond James raised Viking Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $115.00 to $116.00 in a report on Thursday.May 16 at 10:46 AM | marketbeat.comViking Therapeutics' (VKTX) Buy Rating Reaffirmed at Truist FinancialTruist Financial reaffirmed a "buy" rating and issued a $120.00 price objective on shares of Viking Therapeutics in a research note on Thursday.May 16 at 7:00 AM | investorplace.comTiny but Mighty: 3 Small-Cap Stocks Crushing the Russell 2000May 15 at 6:21 PM | benzinga.comHere's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth TodayMay 14, 2024 | investorplace.comDouble-Up Delights: 7 Stocks Poised to Soar 100% by 2025May 13, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 3.4% Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 3.4%May 13, 2024 | finance.yahoo.comIs Viking Therapeutics the Best Biotech Stock for You?May 13, 2024 | fool.comHow Viking Therapeutics Stock Could 30xMay 11, 2024 | marketbeat.comRussell Investments Group Ltd. Makes New $4.78 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Russell Investments Group Ltd. bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 256,633 shares of the biotechnology company's sMay 10, 2024 | investorplace.comThe 3 Best Russell 2000 Stocks to Buy in May 2024May 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 7, 2024 | cnbc.comAmgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominanceMay 6, 2024 | marketbeat.comLisanti Capital Growth LLC Makes New $6.49 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Lisanti Capital Growth LLC acquired a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 348,970 shares of the biMay 6, 2024 | finance.yahoo.comViking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 72% of the companyMay 6, 2024 | marketbeat.comEli Lilly Gains on the GLP-1 Weight Loss Phenomenon (VKTX)Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugsMay 4, 2024 | insidertrades.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 66,756 Shares of StockMay 3, 2024 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) CFO Greg Zante Sells 66,756 SharesViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 66,756 shares of the firm's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total value of $4,986,005.64. Following the transaction, the chief financial officer now directly owns 174,854 shares of the company's stock, valued at $13,059,845.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 3, 2024 | insidertrades.comViking Therapeutics, Inc. (NASDAQ:VKTX) COO Marianna Mancini Sells 281,425 SharesMay 2, 2024 | investorplace.comWhat Is the Best Weight Loss Stock to Buy Now? Our Top 3 PicksMay 2, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.1% Viking Therapeutics (NASDAQ:VKTX) Shares Down 2.1%May 2, 2024 | marketbeat.comJFG Wealth Management LLC Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)JFG Wealth Management LLC purchased a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,000 shares of the biotechnology company's sMay 1, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 4%Viking Therapeutics (NASDAQ:VKTX) Shares Down 4%May 1, 2024 | benzinga.comHere's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 YearsMay 1, 2024 | investorplace.comStock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices PlungeApril 30, 2024 | fool.comViking Therapeutics Delivers Smaller-Than-Expected Q1 LossApril 30, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 1%Viking Therapeutics (NASDAQ:VKTX) Trading Up 1%April 29, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Up 0.6%Viking Therapeutics (NASDAQ:VKTX) Shares Up 0.6%April 28, 2024 | fool.comIs Viking Therapeutics Incredibly Undervalued?April 28, 2024 | fool.comCan This High-Flying Stock 10x in 10 Years?April 26, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 0.3%Viking Therapeutics (NASDAQ:VKTX) Shares Down 0.3%April 26, 2024 | msn.comViking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEOApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viking Therapeutics Amidst Strong Clinical Progress and Strategic MovesApril 26, 2024 | finance.yahoo.comViking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call TranscriptApril 25, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.6% on Strong EarningsViking Therapeutics (NASDAQ:VKTX) Shares Up 1.6% After Strong EarningsApril 25, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Announces Earnings ResultsViking Therapeutics (NASDAQ:VKTX - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. During the same quarter last year, the company posted ($0.25) earnings per share.April 25, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $90.00 price target on shares of Viking Therapeutics in a research report on Thursday.April 24, 2024 | investorplace.comVKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024April 24, 2024 | finance.yahoo.comViking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 24, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.8%Viking Therapeutics (NASDAQ:VKTX) Trading 1.8% HigherApril 24, 2024 | investorplace.com3 Biotech Stocks With Skyrocketing Potential: April 2024 Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s PRIME is Set to Shock the World (Ad)Must-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing. Click here for the full story… VKTX Media Mentions By Week VKTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼0.620.50▲Average Medical News Sentiment VKTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼207▲VKTX Articles Average Week Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Roivant Sciences News Today Legend Biotech News Today Ascendis Pharma A/S News Today Cerevel Therapeutics News Today Catalent News Today Jazz Pharmaceuticals News Today Intra-Cellular Therapies News Today Cytokinetics News Today Elanco Animal Health News Today Blueprint Medicines News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
